Skip to main content
MXCT
NASDAQ Industrial Applications And Services

MaxCyte 10-Q: Q3 Revenue Up 49% to $10.2M, Net Loss Narrows to $4.8M Ahead of $151.8M Akron Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.19
Mkt Cap
$116.623M
52W Low
$0.643
52W High
$1.805
52W Position info
85% above low
Off High info
34% below high
Rel. Volume info
4.5× avg
Market data snapshot near publication time

MXCT sits 85% above its 52-week low of $0.643 on elevated volume (4.5× avg).

Summary

MaxCyte's Q3 10-Q shows revenue up 49% to $10.2 million and the net loss cut to $4.8 million, while detailing how the $151.8 million Akron Bio acquisition will be funded with $105 million of cash, 20.6 million new shares and a new $75 million MidCap credit facility.


Key Events · Earnings and Guidance · MXCT

  • Q3 Revenue Jumps 49%

    Total revenue was $10.152 million versus $6.829 million a year ago, with core revenue up 27% to $8.157 million and SPL milestone and royalty revenue up 372% to $1.995 million.

  • Net Loss Narrowed Sharply

    Q3 net loss fell to $4.762 million from $12.416 million, and the nine-month loss to $18.386 million from $35.034 million, as operating expenses dropped to $14.509 million from $19.382 million.

  • Akron Deal Funding and Dilution

    The $151.8 million Akron Bio purchase is $105.0 million cash, 20,639,733 shares valued at about $26.8 million, and $20.0 million of guaranteed deferred payments due January 2028 and January 2029; the share issuance equals roughly 20% of the 103,233,238 shares outstanding at September 30, 2026.

  • New $75M MidCap Credit Facility

    A commitment letter provides a $55.0 million term loan in four tranches at SOFR plus 5.25% and a $20.0 million revolver at SOFR plus 3.75%; MaxCyte expects to draw $20.0 million and $2.0 million respectively at closing, with both maturing five years after closing.


Analysis · MXCT · Industrial Applications And Services

Hard GAAP numbers now back this morning's pre-announcement: Q3 revenue of $10.2 million (up 49%) and a net loss of $4.8 million versus $12.4 million a year ago, with gross margin at 83%. Cost cuts from the September 2025 restructuring are visible — nine-month R&D is down 37% and sales and marketing down 29%. Against that, the company is committing $105 million of cash to buy Akron Bio, which will consume most of its $132.7 million of cash and investments and require the new $75 million MidCap facility, of which $22 million is expected to be drawn at closing. The 20.6 million shares issued as consideration add roughly 20% to the 103.3 million shares outstanding, and the $20 million of guaranteed deferred payments are owed in 2028 and 2029 regardless of Akron's performance. The deal is expected to close before the end of 2026, subject to customary conditions.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MXCT was trading at $1.19 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $116.6M. The 52-week trading range was $0.64 to $1.81. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MXCT - Latest Insights

MXCT
Nov 10, 2026, 12:40 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $1.15 info
Change: -$0.0050 (-0.43%) info
Market Cap: $118.687M info
MXCT
Nov 10, 2026, 8:21 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.36
Real-time Price: $1.15 info
Change: -$0.210 (-15%) info
Market Cap: $118.687M info
MXCT
Nov 10, 2026, 6:01 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $1.15 info
Change: -$0.280 (-20%) info
Market Cap: $118.687M info
MXCT
Nov 10, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $1.15 info
Change: -$0.0804 (-7%) info
Market Cap: $118.687M info
MXCT
Oct 14, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.00
Real-time Price: $1.15 info
Change: +$0.150 (+15%) info
Market Cap: $118.687M info